Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable, accrued, and other liabilities | (33) | (58) |
| Net cash used in operating activities | (294) | (275) |
| Investing activities: | ||
| Purchase of property, plant, and equipment | (2) | (4) |
| Purchase of marketable securities | (188) | (16) |
| Proceeds from sale of marketable securities | 38 | — |
| Proceeds from maturities of marketable securities | 155 | 226 |
| Payments for intangible asset | (5) | (15) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's capex?
- Ultragenyx Pharmaceutical (RARE) reported capex of $1M in Q2 2026.
- How has Ultragenyx Pharmaceutical's capex changed year-over-year?
- Ultragenyx Pharmaceutical's capex decreased by 66.7% year-over-year, from $3M to $1M.
- What is the long-term trend for Ultragenyx Pharmaceutical's capex?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's capex has grown at a -46.5% compound annual growth rate (CAGR), from $73.09M to $6M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Ultragenyx Pharmaceutical's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude